STUDY THE TREATMENT PROCEDURE PROSTATE CANCER AND NEUROENDOCRINE TUMOR (NET) USING RADIOACTIVE MATERIAL LU-177
- Authors
-
-
Aqeel Mitham Sabr
Department of Medical Physics, College of Science University of Karkh -
Maryam fakhry saeed
Department of Medical Physics, College of Science University of Karkh -
Aliaa Jassim Mohammed
Department of Medical Physics, College of Science University of Karkh -
Tuqa Azhar Nabeel
Department of Medical Physics, College of Science University of Karkh
-
- Abstract
- Lu-177 prostate-specific membrane antigen (PSMA) radioligand ther-apy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. The cur-rent literature suggests that this therapy is well tolerated and effective. On the basis of clinical need and current evidence, the therapy is being implemented in a growing number of centers worldwide. Here, we review important aspects of Lu-177 PSMA RLT, including patient stratification, the therapy protocol, concomitant medication, and follow- up, to inform medical staff involved in the RLT and care of patients with metastatic castration- resistant prostate cancer. Introduction: Lutetium-177 It is a radioactive substance characterized by the Release of beta (β) radiation, which has a very weak diffusion Diameter (less than 1.7 mm), and (half-life 6.7 days),which helps direct therapeutic rays Only to cells affected by cancer without greatly affecting Neighboring cells . Lutetium-177 PSMA (Prostate specific membrane antigen) Treatment is a form of radionuclide therapy that alms to destroy Prostate cancer cells that have spread into parts of the body, Including diagnosis and treat men with prostate cancer.